Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants

NCT06291311 · tracked via the Priya Life Science Germany tracker

Sponsor

University Hospital Tuebingen

Phase

Observational

Started

2023-12-27

Last updated

2026-06-30

Condition(s) studied

HPV InfectionCervical Cancer

Investigational drug(s) / intervention(s)

Cold physical PlasmaControl group

Cold physical Plasma: The treatment is administered by either the supervising specialists or assistant doctors at the University Women's Hospital, under their supervision and authorization. It's important to note that the NIPP treatment is designed to be relatively brief, with a duration not exceeding 10-20 minutes.

Control group: A potential natural healing of the HPV infection will be anticipated

Study summary

This is a prospective, single-center, observational proof-of-principle clinical trial at the Department of Women's Health of the University Hospital Tübingen.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Inclusion criteria for NIPP treatment * Age ≥ 18 years * mRNA or DNA-based virus detection by smear (also external findings) * Clearly visible transformation zone of the cervix and margins of the lesions corresponding to T1/T2 * Written informed consent to participate in the study * Inclusion criteria for control group * Age ≥ 18 years * Swab-based mRNA or DNA-based virus detection (also external findings) * Clearly visible transformation zone of the cervix corresponding to T1/T2 * Written informed consent to participate in the study Exclusion criteria: The following exclusion criteria apply to both groups of patients (NIPP treatment and control group). * Transformation zone not fully visible * Evidence of invasive disease * Serious cardiovascular diseases

Primary outcome measure(s)

HPV eradication rate — 3-6 months
In the following intervention study, participants will be tested for HPV infection before and after NIPP treatment.

Trial sites (1)

Facility	City	Region	Status
University Hospital Tuebingen, Department of Women's Health	Tübingen	Germany	Recruiting

More University Hospital Tuebingen trials in Germany

A Strong Start in Life - ELAS 2.0: A Digital Learning Program to Promote a Healthy Pregnancy and Early Child Protection Starting soon

Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adults Recruiting

PREG - Offspring: Investigation of Children From Mothers With and Without Gestational Diabetes Recruiting

The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4 Recruiting

Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac Recruiting

Other trials for the same condition

MR-guidance in Chemoradiotherapy for Cervical Cancer Recruiting

International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer Active, not recruiting

German-funded Laparoscopic Approach to Cervical Cancer Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) Active, not recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06291311 on ClinicalTrials.gov ↗ ← All trials in Germany